Managing Innovation to Maximize Value Along the Discovery‐Translation‐Application Continuum
暂无分享,去创建一个
[1] G. Gores,et al. Regenerative Medicine Build-Out , 2015, Stem cells translational medicine.
[2] N Parrott,et al. Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective , 2015, Clinical pharmacology and therapeutics.
[3] S P Hoerstrup,et al. Organ Chips: Quality Assurance Systems in Regenerative Medicine , 2017, Clinical pharmacology and therapeutics.
[4] K. Venkatakrishnan,et al. Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science , 2017, Clinical pharmacology and therapeutics.
[5] R. Hohl. Oncology trial design: More accurately and efficiently advancing the field , 2015, Clinical pharmacology and therapeutics.
[6] D. Vujović,et al. Longitudinal Cystic Fibrosis Care , 2013, Clinical pharmacology and therapeutics.
[7] CJ Musante,et al. Quantitative Systems Pharmacology: A Case for Disease Models , 2016, Clinical pharmacology and therapeutics.
[8] K. Kaitin,et al. The Biotechnology Innovation Machine: A Source of Intelligent Biopharmaceuticals for the Pharma Industry—Mapping Biotechnology's Success , 2014, Clinical pharmacology and therapeutics.
[9] F. Hirsch,et al. Innovative Clinical Trials: The LUNG‐MAP Study , 2015, Clinical pharmacology and therapeutics.
[10] S‐M Huang,et al. Intelligent Pharmaceuticals: Beyond the Tipping Point , 2014, Clinical pharmacology and therapeutics.
[11] S. Amur,et al. Catalyzing the critical path initiative: FDA's progress in drug development activities , 2015, Clinical pharmacology and therapeutics.
[12] A. Terzic,et al. Bioinnovation Enterprise: An engine driving breakthrough therapies , 2016, Clinical pharmacology and therapeutics.
[13] M. Calos,et al. Genome Editing Techniques and Their Therapeutic Applications , 2017, Clinical pharmacology and therapeutics.
[14] Y. Fujita,et al. Regenerative medicine legislation in Japan for fast provision of cell therapy products , 2016, Clinical pharmacology and therapeutics.
[15] R. W. Hansen,et al. Journal of Health Economics , 2022 .
[16] K. Venkatakrishnan,et al. Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities , 2015, Clinical pharmacology and therapeutics.
[17] M. Deren. Beyond the tipping point. , 2013, Connecticut medicine.
[18] JG Allickson. Emerging Translation of Regenerative Therapies , 2017, Clinical pharmacology and therapeutics.
[19] I. König,et al. What is precision medicine? , 2017, European Respiratory Journal.
[20] D. Shlaes,et al. A Pharmaceutical Industry Perspective , 2004 .
[21] I Zineh,et al. Improving the tools of clinical pharmacology: Goals for 2017 and beyond , 2017, Clinical pharmacology and therapeutics.
[22] S. Schneeweiss,et al. Improving therapeutic effectiveness and safety through big healthcare data , 2016, Clinical pharmacology and therapeutics.
[23] H. Volk,et al. Clinical Development of Cell Therapies: Setting the Stage for Academic Success , 2017, Clinical pharmacology and therapeutics.
[25] D. Longo,et al. Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma , 2017, Clinical pharmacology and therapeutics.
[26] A. Terzic,et al. Big Data Transforms Discovery–Utilization Therapeutics Continuum , 2016, Clinical pharmacology and therapeutics.
[27] J. Tait,et al. Challenges and opportunities. , 1996, Journal of psychiatric and mental health nursing.
[28] J. Li,et al. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor? , 2017, Clinical pharmacology and therapeutics.
[29] P. Calabresi,et al. Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis , 2017, Clinical pharmacology and therapeutics.